Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
ReviewFOXM1: From cancer initiation to progression and treatment☆
Highlights
► The FOXM1 transcription factor is a regulator of a broad range of biological processes. ► Elevated and deregulated FOXM1 expression is found in a wide spectrum of cancers. ► FOXM1 also plays a central role in cancer initiation, progression and anti-cancer drug resistance. ► This review summarises the role and regulation of FOXM1 in various aspects of cancer.
Introduction
Forkhead box protein M1 (FOXM1), also formerly known as HFH-11, MPP-2, WIN, and Trident, belongs to the Forkhead superfamily of transcription factors which all share an evolutionary conserved ‘winged helix’ DNA-binding domain. It regulates the expression of a plethora of target genes through binding to the consensus sequence, TAAACA [1], [2]. The human FOXM1 gene, consisting of 10 exons, is mapped to chromosome 12p13-3 [1]. Of the 10 exons, exon Va (A1) and exon VIIa (A2) are alternatively spliced, giving rise to 3 distinct variants: FOXM1a, -b and -c [3]. The FOXM1a isoform is transcriptionally inactive as it harbours both the Va and VIIa exons, resulting in the disruption of the transactivation domain by the exon VIIa. However, as FOXM1a can still bind DNA it is considered to be a dominant negative regulator of other FOXM1 isoforms. On the other hand both FOXM1b, which contains neither of the two exons, and FOXM1c, which has the Va exon only, are transcriptionally active and can directly promote target gene expression in an isoform-specific manner.
The FOXM1 transcription factor plays an essential role in the regulation of a wide spectrum of biological processes, including cell proliferation, cell cycle progression, cell differentiation, DNA damage repair, tissue homeostasis, angiogenesis and apoptosis. Elevated expression of FOXM1 is also observed in a multitude of malignancies, including cancers of the liver, prostate, brain, breast, lung, colon, pancreas, skin, cervix, ovary, mouth, blood and nervous system [[4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18]]. Genome-wide gene expression profiling of cancers has independently and consistently identified FOXM1 as one of the most commonly upregulated genes in human solid tumours [[19], [20], [21]]. These findings point to a principal role for FOXM1 in tumorigenesis. In addition, recent research also links FOXM1 deregulation to cancer progression and the development of cancer drug resistance. Consequently, extensive studies have been conducted to better understand the regulation and roles of FOXM1 during tumorigenesis and the development of cancer drug resistance (Fig. 1).
Section snippets
Cell cycle and proliferation
FOXM1 is one of a few genes shown to be upregulated during early cancer development [[2], [20], [22], [23], [24]]. The involvement of FOXM1 in the onset of tumorigenesis largely relates to its role in cell cycle progression and proliferation. FOXM1 is a key regulator for G1/S and G2/M transition, and M phase progression. Besides regulating Cdc25A expression at the G1/S checkpoint, FOXM1 also controls the transcription of Skp2 and Cks1, which are substrate-targeting subunits of the
FOXM1 in cancer progression
In cancer progression tumour initiation is followed by tumour promotion. Besides its initial role in tumorigenesis, FOXM1 can also promote multiple steps of cancer progression by inducing mitogenic and survival signals, as well as promoting tumour invasion, migration and angiogenesis [40]. To halt cancer progression, chemotherapies must ideally be administered earlier in cancer development and be targeted specifically at the disease mechanisms. In this respect, there is sufficient evidence to
Cancer chemotherapy drugs and resistance
Systemic chemotherapy is used to treat the majority of people diagnosed with cancer. It is also the mainstay of treatment for leukaemia and other advanced or metastatic solid cancers [[63], [64], [65], [66]]. Conventional chemotherapeutics can stop these cancer cells from multiplying and spreading, but their cytotoxic function can be fairly unspecific, resulting in damage to healthy cells. As a consequence, cancer therapies have been developed recently to target specific cellular molecules
Conclusion and future perspectives
Ongoing studies of FOXM1 have provided a fascinating perspective on its role and regulation in cancer development and drug resistance. The FOXM1 transcription factor plays a central role in the regulation of a multitude of cellular functions, including cell proliferation, cell survival, and immortalisation, which are essential for tumorigenesis. An understanding of the FOXM1 function and how it is regulated will undoubtedly provide new clues in deciphering the mechanisms of tumorigenesis and
References (116)
- et al.
The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization
Genomics
(1997) - et al.
FoxM1: at the crossroads of ageing and cancer
Biochim. Biophys. Acta
(2007) - et al.
Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain
J. Biol. Chem.
(1997) - et al.
The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells
J. Biol. Chem.
(2006) - et al.
The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer
Gastroenterology
(2007) - et al.
Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data
Neoplasia
(2004) - et al.
Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy
Am. J. Pathol.
(2011) - et al.
New and unexpected: forkhead meets ARF
Curr. Opin. Genet. Dev.
(2005) - et al.
FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression
J. Biol. Chem.
(2008) - et al.
Increased expression of FoxM1 transcription factor in respiratory epithelium inhibits lung sacculation and causes Clara cell hyperplasia
Dev. Biol.
(2010)
Forkhead box M1 transcriptional factor is required for smooth muscle cells during embryonic development of blood vessels and esophagus
Dev. Biol.
The mouse Forkhead Box m1 transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis
Dev. Biol.
Ubiquitous expression of the forkhead box M1B transgene accelerates proliferation of distinct pulmonary cell types following lung injury
J. Biol. Chem.
Earlier expression of the transcription factor HFH-11B diminishes induction of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte entry into S-phase following carbon tetrachloride liver injury
Hepatology
MMP9 potentiates pulmonary metastasis formation
Cancer Cell
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group
Ann. Oncol.
Identification of cyclin A2 as the downstream effector of the nuclear phosphatidylinositol 4,5-bisphosphate signaling network
J. Biol. Chem.
FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines
J. Biol. Chem.
FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1
J. Biol. Chem.
Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions
Oncogene
Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice
Cancer Res.
The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer
Cancer Res.
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells
Cancer Res.
Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells
Cancer Res.
Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis
J. Pathol.
FOXM1 is a downstream target of Gli1 in basal cell carcinomas
Cancer Res.
Integrated genomic analyses of ovarian carcinoma
Nature
FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation
PLoS One
Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes
Mol. Cancer
Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma
Genes Chromosom. Cancer
FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells
J. Cell. Physiol.
The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia
Carcinogenesis
Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression
Cancer Res.
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer
Int. J. Oncol.
Identification of early molecular markers for breast cancer
Mol. Cancer
Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase
Mol. Cell. Biol.
FoxM1 is required for execution of the mitotic programme and chromosome stability
Nat. Cell Biol.
Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe
Cancer Res.
Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor
Genes Dev.
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment
J. Clin. Invest.
Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators
Mol. Cell. Biol.
Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain
Mol. Cell. Biol.
Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c
J. Cell Sci.
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression
Nat. Cell Biol.
FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1
J. Pathol.
Induction of human epithelial stem/progenitor expansion by FOXM1
Cancer Res.
Sox2 activates cell proliferation and differentiation in the respiratory epithelium
Am. J. Respir. Cell Mol. Biol.
Foxm1 transcription factor is required for maintenance of pluripotency of P19 embryonal carcinoma cells
Nucleic Acids Res.
The emerging roles of forkhead box (Fox) proteins in cancer
Nat. Rev. Cancer
Endothelial cell-specific deletion of transcription factor FoxM1 increases urethane-induced lung carcinogenesis
Cancer Res.
Cited by (336)
Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatments
2023, Biochimica et Biophysica Acta - Reviews on CancerActivation of LXRα attenuates 2-Ethylhexyl diphenyl phosphate (EHDPP) induced placental dysfunction
2023, Ecotoxicology and Environmental SafetyWNT5A: a double-edged sword in colorectal cancer progression
2023, Mutation Research - Reviews in Mutation Research
- ☆
Grant support: Cancer Research UK and Breast Cancer Campaign (E.W.-F. Lam) and Imperial College Healthcare NHS Trust – BRC Funding (E.W.-F. Lam, C.-Y. Koo).